Resuscitation Drugs and Pharmacotherapy

Resuscitation pharmacotherapy comprises the drugs given during cardiac arrest to support perfusion and rhythm while chest compressions and defibrillation are ongoing. The principal classes are vasopressors, which aim to raise perfusion pressure during compressions, and antiarrhythmic agents, used as an adjunct in shock-refractory shockable rhythms.

Definition

Resuscitation drugs are the pharmacological agents administered during cardiac arrest — chiefly vasopressors to support perfusion pressure and antiarrhythmics for refractory shockable rhythms — used as adjuncts to high-quality chest compressions and defibrillation within advanced life support.

Scope

This topic covers the rationale and evidence for the main drug classes used during cardiac arrest — vasopressors and antiarrhythmics — and how they sit within advanced life support alongside compressions and defibrillation. It is descriptive and educational and deliberately gives no doses, routes, intervals, or individualized treatment recommendations; those follow current guidelines and formal training.

Key concepts

• Vasopressors and perfusion pressure during compressions
• Antiarrhythmic agents for shock-refractory shockable rhythms
• Drugs as adjuncts to compressions and defibrillation
• Outcomes: return of spontaneous circulation versus survival and neurological outcome
• Reversible causes and cause-directed therapy
• Place of pharmacotherapy within advanced life support

Mechanisms

Vasopressors act on vascular tone to raise systemic vascular resistance, with the aim of increasing coronary and cerebral perfusion pressure generated by chest compressions and thereby improving the chance of restoring a spontaneous circulation. Antiarrhythmic agents act on cardiac ion channels to stabilize the myocardium and are used to support defibrillation when a shockable rhythm persists despite shocks. Because these drugs are adjuncts, their effect is tightly coupled to the quality of compressions and the timeliness of defibrillation; trial evidence distinguishes their effect on short-term endpoints such as return of spontaneous circulation from their effect on survival and neurological outcome, which is where the central debate lies.

Clinical relevance

Resuscitation pharmacotherapy is a defined component of advanced life support, layered onto high-quality compressions and defibrillation. This entry summarizes the drug classes and their evidence for reference only; it gives no dosing or administration guidance, and actual drug selection, timing, and dosing follow current resuscitation guidelines and formal training rather than this summary.

Epidemiology

Cardiac arrest carries high mortality, and the marginal contribution of individual drugs to long-term survival is modest relative to early compressions and defibrillation, which is why large randomized trials have focused on whether specific agents improve survival and neurological outcome rather than only short-term resuscitation success.

Evidence & guidelines

The role of resuscitation drugs is defined in the advanced life support guidelines of the European Resuscitation Council and the American Heart Association. Randomized trials of a vasopressor versus placebo and of antiarrhythmic agents versus placebo in out-of-hospital cardiac arrest provide the key evidence those guidelines weigh.

History

Drugs were incorporated into resuscitation as advanced life support was formalized in the second half of the twentieth century. Their role has been progressively scrutinized by randomized trials, which clarified that some agents improve return of spontaneous circulation more clearly than they improve survival with good neurological function, prompting more cautious and evidence-weighted guideline recommendations.

Debates

Do resuscitation drugs improve survival with good neurological outcome?

A large placebo-controlled trial of a vasopressor in out-of-hospital cardiac arrest improved return of spontaneous circulation but did not show a clear benefit in survival with favourable neurological outcome, and antiarrhythmic trials have shown limited or subgroup-dependent benefit, keeping the net value of resuscitation pharmacotherapy a continuing point of debate.

Seminal works

• soar-2021
• panchal-2020
• perkins-2018
• kudenchuk-2016

Frequently asked questions

What are the main drug classes used during cardiac arrest?

The principal classes are vasopressors, which aim to raise perfusion pressure generated by chest compressions, and antiarrhythmic agents, used as an adjunct for shockable rhythms that persist despite defibrillation.

Are resuscitation drugs as important as compressions and defibrillation?

No; drugs are adjuncts. Evidence indicates that early high-quality compressions and prompt defibrillation carry most of the survival benefit, while the contribution of individual drugs to survival with good neurological outcome is more limited and is an area of ongoing study.